** Shares of Janux Therapeutics JANX.O rise 67.5% to $67.34 premarket
** Data from early-stage trial shows all 16 patients with a type of prostate cancer that used co's experimental drug JANX007 achieved declines in levels of prostate-specific antigens
** Drug also had "well-tolerated safety profile" and "maximum tolerable dose has not yet been reached"
** Co selects 2 once-weekly dose regimens when expanding early-stage trial based on results
** BTIG analyst Justin Zelin said investor concerns were expectations may have been too high ahead of the results, but JANX's data exceeded expectations and was "unprecedented"
** Brokerage raises PT to Street-high of $100 from $82
** 12 brokerages rate the stock "buy" or higher, 1 "hold"; their median PT is $70 - LSEG
** As of last close, stock had risen 274.5% YTD
(Reporting by Leroy Leo in Bengaluru)
((Leroy.Dsouza@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。